While first line targeted therapies are the current standard of care treatment for non-small
cell lung cancer (NSCLC) with actionable mutations, the cancer cells inevitably acquire …

Six ALK TKIs (crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, ensartinib) have received
first-line treatment indication of advanced ALK+ NSCLC in various countries. In Ba/F3 cells …

Introduction Lorlatinib was found to have activity in ALK-positive NSCLC in a global phase 1
and 2 study. We report an ongoing phase 2 study in Chinese patients with ALK-positive …

Overall survival in metastatic lung cancer has been dramatically improved with the use of
small molecule kinase inhibitors (SMKIs). Quantification of SMKI in cerebrospinal fluid (CSF) …

The 15th edition of the Workshop on Recent Issues in Bioanalysis (15th WRIB) was held on
27 September to 1 October 2021. Even with a last-minute move from in-person to virtual, an …

Objectives To analyze the efficacy and safety of lorlatinib in Asian and non-Asian patients
with pretreated anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung …

The use of tyrosine kinase inhibitors has made a breakthrough in the treatment of non-small-
cell lung cancer (NSCLC). Recently, lorlatinib, a third-generation tyrosine kinase inhibitor …

Lorlatinib, a third-generation ALK tyrosine kinase inhibitor, has been approved as a
treatment for ALK-positive lung cancer. This review provides information regarding the …

Backgrounds: Brain metastases occur in approximately 30% of patients with non-small-cell
lung cancer (NSCLC). Therefore, the free drug concentration in cerebrospinal fluid (CSF) is …

Objectives Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) inhibitor, causes
distinct adverse events (AEs), including hyperlipidemia and central nervous system (CNS) …